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In classic Hodgkin lymphoma (cHL), Epstein Barr virus (EBV) association
varies worldwide.
Aims: Our aim was to analyze EBV association with pediatric cHL for the last 28 years.
Methods: EBV presence was evaluated by EBERs in situ hybridization and
LMP1 immunohistochemistry.
Results: Until 2008, we found in pediatric cHL a similar percentage of EBV presence
to those observed in adult cHL from developed populations. Nevertheless, in the last 8
years, an unexpected difference in cHL EBV association was proven, along with a slight
bias of EBV association with the nodular sclerosis (NS) subtype. Concerning histological
subtype distribution, even though MC still prevailed in the whole series, those cases
diagnosed as NS showed a sustained rise from 1989 until today.
Conclusion: Variations of EBV association of cHL related to geography, age, ethnicity,
and histological type have been largely described when compared with different world
regions, but interestingly, this single-center revised series brought to light the dynamic
process behind the evolution of this relationship over time.
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INTRODUCTION
Epstein Barr virus (EBV) is related to more than 200,000 cases of cancer every year; moreover,
1.8% of all cancer deaths are caused by EBV-related neoplasias1. The three major types of B cell
malignancies associated to EBV are Burkitt, classic Hodgkin, and diffuse large B cell lymphomas
(BL, cHL, and DLBCL), in which EBV presence varies from 10 to 100% of cases in BL, ∼50%
in cHL, and ∼10% in DLBCL. In addition, EBV is associated in 100% of cases with T/NK
lymphoproliferations and nasopharyngeal carcinoma, as well as in ∼10% in gastric carcinoma (1).
Nevertheless, EBV association is not a requisite for them to occur as denoted by their occurrence,
in variable proportion, in the absence of EBV as well (2). CHL is subclassified into nodular
sclerosis (NS), mixed cellularity (MC), lymphocyte-rich (LRHL), and lymphocyte-depleted (LDHL)
(3). CHL includes three different disease entities: pediatric HL (EBV-positive, mixed cellularity
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subtype), HL in young adults (EBV-negative, nodular sclerosis
subtype), and HL in older adults (EBV-positive, mixed cellularity
subtype) (4). In European and North American reports, tumor
cells are infected by EBV in ∼40% of cHL cases (5). However,
EBV association with cHL shows a different age distribution
in underdeveloped or developing populations, mostly as a
consequence of socioeconomic status, but also attributable to
other factors, such as race or ethnicity, suggesting an interplay
between environmental and genetic factors related to the etiology
of EBV-positive cHL. In fact, it was demonstrated that EBV
presence in US- and foreign-born Hispanics was increased in
patients aged 0–14 years and older than 55 years, while among
whites, EBV-positive cases were observed mostly in patients
older than 40 years (6). However, in a series of pediatric cHL
from Brazil, EBV-associated cases were not specifically found in
younger patients (7).
Racial/ethnic differences showed higher HL rates and lower
EBV+ tumor prevalence in whites. In fact, Glaser et al. compared
EBV-associated HL rates in US Hispanics with non-Hispanic
whites, and reported and EBV prevalence of 67, 32, and 23%
among foreign-born Hispanics, US-born Hispanics, and whites,
respectively, revealing how environment affects HL incidence
variation (6). Childhood cHL represents 6% of all cancers in
the 0–14 years age group with a typical male preponderance.
The MC histological subtype is the one mostly associated with
EBV, prevails in young children, and represents around 20% of
HL, while the NS subtype is mostly seen in adolescents and
young adults and denotes about 75% of HL. Tumor cells are EBV
positive in ∼30 and 90% of all pediatric HL cases in developed
and underdeveloped or developing countries, respectively (8).
Those facts clearly demonstrated that EBV association rates
of cHL vary among populations, based on differences in both
environmental and genetic features. Socioeconomical factors,
such as poverty, childmortality, illiteracy, unsatisfied basic needs,
and running water, may fluctuate in countries like Argentina
during a long time period, showing evidence of a dynamic
scenario. Our previous work, which included pediatric pre-
operative serum samples from patients younger than 15 years
old, demonstrated that 72% of children were seropositive for EBV
by the age of 3 years (9). Therefore, since no previous studies
have examine temporal trends of cHL in an Argentine pediatric
cohort, our aim was to analyze the course of pediatric cHL
features in a single institution for the last 28 years, particularly
in relation to EBV.
MATERIALS AND METHODS
Patients and Samples
Formalin-fixed paraffin-embedded (FFPE) biopsy samples from
174 patients were collected from the archives at Pathology
Division, Ricardo Gutierrez Children’s Hospital, a national
referent institution that receives cases from the whole country,
from 1989 to 2017. Diagnosis was performed from primary
biopsies according to the WHO scheme (10). Institutional
guidelines regarding human experimentation in accordance with
the Helsinki Declaration of 1975 were followed. The Ethical
Committee of the Ricardo Gutierrez Children Hospital has
approved the study, and patients’ guardians provided written
informed consent in accordance with the Declaration of Helsinki.
EBV Analysis
EBERs in situ hybridization (ISH) was performed on the 174
FFPE tissue sections using fluorescein isothiocyanate (FITC)-
conjugated EBERs oligonucleotides as probes (Dako) according
to the manufacturer’s instructions. A monoclonal antibody
anti-FITC labeled with alkaline phosphatase was used for
the detection of hybridized sites (Dako). An EBV-associated
post-transplant lymphoproliferative disorder was used as a
positive control.
Immunostaining using monoclonal antibodies CS1-4 (Dako)
was performed to localize LMP1 expression. Primary antibodies
were incubated overnight at 4◦C. IHC detection of primary
antibodies was carried out using a universal streptavidin–
biotin complex-peroxidase detection systemUltraTek HRP Anti-
Polyvalent Lab Pack (ScyTek) as previously described (11).
An EBV-associated post-transplant lymphoproliferative disorder
biopsy was used as a positive control, and a negative control was
performed without the primary antibody.
Statistical Analysis
Categorical variables (EBV presence, age group, gender, HL
subtypes) were analyzed using Fisher’s exact test. Mann–Whitney
test was used to compare the age means in relation to EBV
presence and histological subtypes. The Cochran–Armitage
test was used to assess differences in the percentage of EBV
positive cases, or subtype distribution during the five periods.
Survival distributions were estimated with the Kaplan–Meier
method, and the differences were compared by the log-rank
test. All tests were two-tailed, and a p < 0.05 was considered
statistically significant.
RESULTS
EBV association with cHL was observed in 103/174 patients
(59%) by EBERs ISH and LMP1 expression. As expected, EBV
was statistically associated to MC subtype since it was observed
in 65/84 (77%) of cases, compared to 25/65 (38%) in NS, 10/20
(50%) in LRHL, and 3/5 (60%) in LDHL (p < 0.0001, Fisher
exact test). In addition, EBV presence was statistically associated
with patients younger than 10 years old (68% of EBV+ cases)
(p = 0.0003, Fisher exact test) and males (98% of EBV+ cases)
(p= 0.009, Fisher exact test).
When EBV association was analyzed by discriminating five
periods, unexpectedly, in the last 8 years, a slight increase
in EBV association was observed, given that the 2009–2013
and 2014–2017 periods displayed an EBV positivity of 65 and
72%, respectively (Table 1), although this increase was not
statistically significant (p = 0.169, Cochran–Armitage test for
trend). When analyzing cHL distribution according to age, an
increase in the median age on EBV-associated cases over time
was observed (Supplementary Table 1), but without statistical
significance when EBV+ cases were compared (p = 0.1555,
Kruskal–Wallis test). Finally, when histological subtypes were
analyzed in relation to age in the 28-years period, MC diagnosis
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TABLE 1 | EBV positivity in pediatric cHL according to MC and NS subtypes.








1989–1993 16/29 55 13/18 72 0/5 0
1994–1998 17/34 50 12/18 67 3/11 27
1999–2003 28/44 64 19/21 90 7/20 35
2004–2008 7/15 47 2/6 33 3/6 50
2009–2013 22/34 65 12/14 86 9/15 60
2014–2017 13/18 72 7/7 100 3/8 38
Total 103/174 59 0.169 65/84 77 0.180 25/65 38 0.041*
MC, mixed cellularity; NS, nodular sclerosis. p-value as determined by Cochran–Armitage
test for trend. *p < 0.05.
turned out to be statistically associated with younger patients
(median age MC 7 years, NS 11 years, LRHL 11 years, and LDHL
10 years, p= 0.0006, Kruskal–Wallis test).
In order to explain the slight increase in EBV positivity,
viral association was analyzed deeply throughout the five periods
specifically in both MC and NS prevalent subtypes. Interestingly,
EBV association with NS subtype showed a statistical difference
over time, showing a peak of 60% in the 2009–2013 period
(p= 0.041, Cochran–Armitage test for trend), while MC subtype
showed similar percentages of association with EBV throughout
the analysis (p = 0.180, Cochran–Armitage test for trend)
(Table 1). At this point, the question that arises is if this difference
could be a consequence of an increase in the incidence of NS
subtype itself. Even though the MC subtype still prevails in the
whole series, the proportion of cases diagnosed as NS subtype
showed a statistical increase from 1989 (17%) until today (42%)
(p= 0.024, Cochran–Armitage test for trend), compared with the
MC subtype (Supplementary Table 2).
In our whole pediatric cHL series, EBV status had no
significant influence on prognosis (p = 0.2093, log rank test)
(Figure 1A). Given the fact that EBV has a higher incidence of
cHL among patients under 10 years old, survival analysis was
restricted to this specific group, but the virus did not determine
survival as well (p= 0.3883, log rank test) (Figure 1B).
DISCUSSION
In our cohort, EBV positivity displayed similar percentages to
those observed in developed populations (∼50%), but lower
than the previously described for underdeveloped countries
(∼90%) (3). Regardless of an HL–EBV association resembling
developed countries, the virus was statistically associated with
HL cases occurring in children younger than 10 years, such as
in underdeveloped countries.
Concerning histological subtypes, childhood cHL typically
shows a significant prevalence of MC. In order to further
characterize EBV distribution in HL subtypes, we discriminate
viral presence in both major subtypes, MC and NS. As a
matter of fact, EBV association with the NS subtype showed
FIGURE 1 | Kaplan–Meier survival curves illustrate event-free survival (EFS)
analysis of pediatric cHL cohort related to EBV status in (A) the whole cohort
and (B) patients younger than 10 years old.
a difference in the last years. We suggest that the shift to
NS diagnosis in our pediatric cHL may contribute to the
detection of more EBV-related NS cases and also might explain
the higher EBV presence in our population in the last years.
Several socioeconomic status indicators in Argentina improved
during the last two decades, such as poverty, child mortality,
illiteracy, unsatisfied basic needs, and running water (12), which
possibly could explain the lower cHL incidence along with the
shift toward NS subtype, resembling developed populations.
Nevertheless, EBV infection status was not influenced by this
improvement in our series, given that EBV association with
pediatric cHL did not exhibit any changes in children from our
institution. On the other hand, in children from Brazil, EBV-
associated cHL decreased from 96 to 64% over the last 54-
years period (13), whereas the same finding was demonstrated
in children from Korea, in which a decrease from 21 to 8.6%
was proven (14). An improvement in socioeconomic conditions
in these two populations was suggested to be related to the
change toward a pattern of EBV association similar to developed
populations (13).
The identification of prognostic biomarkers in children that
correlates with clinical outcome is important, especially for those
patients with relapse or refractory disease (8). The prognostic
significance of EBV in pediatric patients with cHL is still
Frontiers in Oncology | www.frontiersin.org 3 September 2019 | Volume 9 | Article 881
De Matteo et al. EBV-Associated Pediatric Hodgkin Lymphoma
controversial. In a large study performed by Claviez et al.
in pediatric cHL with combined treatment modalities, in a
univariate analysis, EBV infection has no influence on overall
survival (OS), but it is associated with an inferior OS in specific
subgroups, such as patients with NS and increased numbers of
Hodgkin Reed Sternberg (HRS) cells. However, LMP1 presence
in HRS cells was proved to be an independent prognostic factor
associated with an inferior OS, with no effect on failure free
survival (FFS) (15). In contrast, several groups reported no
association between EBV and clinical outcome (16), or better
prognosis in EBV+ cases (17). Different outcomes might also
be a consequence of variations in the presence of EBV+ HL
that is related to geography, age, ethnicity, and histological
type (14). Therefore, analyses of EBV association with HL in
specific populations are mandatory. In our whole pediatric
cHL population, even if EBV seems to have an important
role in cHL pathogenesis in young children, it has no impact
on survival.
In summary, in the last 30 years, we have observed
an increase in NS subtype in pediatric cHL from our
institution, along with a difference in the incidence of EBV
in this subtype. Even the fact that EBV association with
pediatric cHL in Argentina is still similar to that observed in
developed populations, the shift of EBV presence in young
children with NS cHL may suggest a detrimental influence
of early-life exposure to viral infection. Improvement of
socioeconomic conditions did not show a positive impact
in EBV-associated cHL in our series, suggesting that others
factors might be involved in viral pathogenesis. These findings
reveal the need for more studies involving pediatric groups
from underdeveloped regions to disclose the complexity
of EBV involvement in the lymphomagenesis process in
pediatric patients.
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